These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 29632047)

  • 1. Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.
    Nguyen EV; Centenera MM; Moldovan M; Das R; Irani S; Vincent AD; Chan H; Horvath LG; Lynn DJ; Daly RJ; Butler LM
    Mol Cell Proteomics; 2018 Aug; 17(8):1470-1486. PubMed ID: 29632047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors.
    Centenera MM; Gillis JL; Hanson AR; Jindal S; Taylor RA; Risbridger GP; Sutherland PD; Scher HI; Raj GV; Knudsen KE; Yeadon T; ; Tilley WD; Butler LM
    Clin Cancer Res; 2012 Jul; 18(13):3562-70. PubMed ID: 22573351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
    Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
    Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutively-active androgen receptor variants function independently of the HSP90 chaperone but do not confer resistance to HSP90 inhibitors.
    Gillis JL; Selth LA; Centenera MM; Townley SL; Sun S; Plymate SR; Tilley WD; Butler LM
    Oncotarget; 2013 May; 4(5):691-704. PubMed ID: 23674566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors.
    Voruganti S; Lacroix JC; Rogers CN; Rogers J; Matts RL; Hartson SD
    J Proteome Res; 2013 Aug; 12(8):3697-706. PubMed ID: 23763277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
    Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
    Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
    He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
    Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion.
    Armstrong HK; Gillis JL; Johnson IRD; Nassar ZD; Moldovan M; Levrier C; Sadowski MC; Chin MY; Tomlinson Guns ES; Tarulli G; Lynn DJ; Brooks DA; Selth LA; Centenera MM; Butler LM
    Sci Rep; 2018 Feb; 8(1):2090. PubMed ID: 29391407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
    Nassar ZD; Mah CY; Centenera MM; Irani S; Sadowski MC; Scott JS; Nguyen EV; Nagarajan SR; Moldovan M; Lynn DJ; Daly RJ; Hoy AJ; Butler LM
    Mol Cancer Res; 2020 Oct; 18(10):1500-1511. PubMed ID: 32669400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry.
    Marrugal Á; Ferrer I; Pastor MD; Ojeda L; Quintanal-Villalonga Á; Carnero A; Molina-Pinelo S; Paz-Ares L
    Cells; 2019 Jul; 8(8):. PubMed ID: 31370342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1.
    Kim HB; Lee SH; Um JH; Oh WK; Kim DW; Kang CD; Kim SH
    Oncotarget; 2015 Nov; 6(34):36202-18. PubMed ID: 26416354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic analysis of proteome and histone post-translational modifications in heat shock protein 90 inhibition-mediated bladder cancer therapeutics.
    Li QQ; Hao JJ; Zhang Z; Krane LS; Hammerich KH; Sanford T; Trepel JB; Neckers L; Agarwal PK
    Sci Rep; 2017 Mar; 7(1):201. PubMed ID: 28298630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors.
    van der Kraan AG; Chai RC; Singh PP; Lang BJ; Xu J; Gillespie MT; Price JT; Quinn JM
    Biochem J; 2013 Apr; 451(2):235-44. PubMed ID: 23379601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
    Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
    PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition.
    Kim HB; Lee SH; Um JH; Kim MJ; Hyun SK; Gong EJ; Oh WK; Kang CD; Kim SH
    Int J Biol Sci; 2015; 11(8):923-34. PubMed ID: 26157347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Redefining the Phenotype of Heat Shock Protein 90 (Hsp90) Inhibitors.
    Wang Y; Koay YC; McAlpine SR
    Chemistry; 2017 Feb; 23(9):2010-2013. PubMed ID: 27862436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition.
    Oikonomopoulou K; Soosaipillai A; Diamandis EP
    Clin Biochem; 2009 Nov; 42(16-17):1705-12. PubMed ID: 19632215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
    Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
    Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression-based chemical genomics identifies heat-shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma.
    Chen MH; Lin KJ; Yang WL; Kao YW; Chen TW; Chao SC; Chang PM; Liu CY; Tzeng CH; Chao Y; Chen MH; Yeh CN; Huang CY
    Cancer; 2013 Jan; 119(2):293-303. PubMed ID: 22810956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
    Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
    Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.